BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 38092728)

  • 1. Niacin restriction with NAMPT-inhibition is synthetic lethal to neuroendocrine carcinoma.
    Nomura M; Ohuchi M; Sakamoto Y; Kudo K; Yaku K; Soga T; Sugiura Y; Morita M; Hayashi K; Miyahara S; Sato T; Yamashita Y; Ito S; Kikuchi N; Sato I; Saito R; Yaegashi N; Fukuhara T; Yamada H; Shima H; Nakayama KI; Hirao A; Kawasaki K; Arai Y; Akamatsu S; Tanuma SI; Sato T; Nakagawa T; Tanuma N
    Nat Commun; 2023 Dec; 14(1):8095. PubMed ID: 38092728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical models of nicotinamide phosphoribosyltransferase inhibitor-mediated hematotoxicity and mitigation by co-treatment with nicotinic acid.
    Tarrant JM; Dhawan P; Singh J; Zabka TS; Clarke E; DosSantos G; Dragovich PS; Sampath D; Lin T; McCray B; La N; Nguyen T; Kauss A; Dambach D; Misner DL; Diaz D; Uppal H
    Toxicol Mech Methods; 2015 Mar; 25(3):201-11. PubMed ID: 25894564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Supplementation of nicotinic acid with NAMPT inhibitors results in loss of in vivo efficacy in NAPRT1-deficient tumor models.
    O'Brien T; Oeh J; Xiao Y; Liang X; Vanderbilt A; Qin A; Yang L; Lee LB; Ly J; Cosino E; LaCap JA; Ogasawara A; Williams S; Nannini M; Liederer BM; Jackson P; Dragovich PS; Sampath D
    Neoplasia; 2013 Dec; 15(12):1314-29. PubMed ID: 24403854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nicotinamide Phosphoribosyltransferase (NAMPT) as a Therapeutic Target in BRAF-Mutated Metastatic Melanoma.
    Audrito V; Managò A; La Vecchia S; Zamporlini F; Vitale N; Baroni G; Cignetto S; Serra S; Bologna C; Stingi A; Arruga F; Vaisitti T; Massi D; Mandalà M; Raffaelli N; Deaglio S
    J Natl Cancer Inst; 2018 Mar; 110(3):. PubMed ID: 29309612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Divergent metabolic responses dictate vulnerability to NAMPT inhibition in ovarian cancer.
    Kudo K; Nomura M; Sakamoto Y; Ito S; Morita M; Kawai M; Yamashita Y; Ito K; Yamada H; Shima H; Yaegashi N; Tanuma N
    FEBS Lett; 2020 May; 594(9):1379-1388. PubMed ID: 31950503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme of the nicotinamide adenine dinucleotide (NAD) salvage pathway, to target glioma heterogeneity through mitochondrial oxidative stress.
    Sharma P; Xu J; Williams K; Easley M; Elder JB; Lonser R; Lang FF; Lapalombella R; Sampath D; Puduvalli VK
    Neuro Oncol; 2022 Feb; 24(2):229-244. PubMed ID: 34260721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer.
    Sampath D; Zabka TS; Misner DL; O'Brien T; Dragovich PS
    Pharmacol Ther; 2015 Jul; 151():16-31. PubMed ID: 25709099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retinal toxicity, in vivo and in vitro, associated with inhibition of nicotinamide phosphoribosyltransferase.
    Zabka TS; Singh J; Dhawan P; Liederer BM; Oeh J; Kauss MA; Xiao Y; Zak M; Lin T; McCray B; La N; Nguyen T; Beyer J; Farman C; Uppal H; Dragovich PS; O'Brien T; Sampath D; Misner DL
    Toxicol Sci; 2015 Mar; 144(1):163-72. PubMed ID: 25505128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual Nicotinamide Phosphoribosyltransferase (NAMPT) and Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors for the Treatment of Drug-Resistant Nonsmall-Cell Lung Cancer.
    Wang K; Ye K; Zhang X; Wang T; Qi Z; Wang Y; Jiang S; Zhang K
    J Med Chem; 2023 Jan; 66(1):1027-1047. PubMed ID: 36595482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation, Release, and Uptake of the NAD Precursor Nicotinic Acid Riboside by Human Cells.
    Kulikova V; Shabalin K; Nerinovski K; Dölle C; Niere M; Yakimov A; Redpath P; Khodorkovskiy M; Migaud ME; Ziegler M; Nikiforov A
    J Biol Chem; 2015 Nov; 290(45):27124-27137. PubMed ID: 26385918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel NAPRT specific antibody identifies small cell lung cancer and neuronal cancers as promising clinical indications for a NAMPT inhibitor/niacin co-administration strategy.
    Cole J; Guiot MC; Gravel M; Bernier C; Shore GC; Roulston A
    Oncotarget; 2017 Sep; 8(44):77846-77859. PubMed ID: 29100430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of NAD+-Dependent Metabolic Processes Induces Cellular Necrosis and Tumor Regression in Rhabdomyosarcoma Models.
    McKay-Corkum GB; Collins VJ; Yeung C; Ito T; Issaq SH; Holland D; Vulikh K; Zhang Y; Lee U; Lei H; Mendoza A; Shern JF; Yohe ME; Yamamoto K; Wilson K; Ji J; Karim BO; Thomas CJ; Krishna MC; Neckers LM; Heske CM
    Clin Cancer Res; 2023 Nov; 29(21):4479-4491. PubMed ID: 37616468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nicotinamide phosphoribosyl transferase (Nampt) is required for de novo lipogenesis in tumor cells.
    Bowlby SC; Thomas MJ; D'Agostino RB; Kridel SJ
    PLoS One; 2012; 7(6):e40195. PubMed ID: 22768255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiotoxicity Associated with Nicotinamide Phosphoribosyltransferase Inhibitors in Rodents and in Rat and Human-Derived Cells Lines.
    Misner DL; Kauss MA; Singh J; Uppal H; Bruening-Wright A; Liederer BM; Lin T; McCray B; La N; Nguyen T; Sampath D; Dragovich PS; O'Brien T; Zabka TS
    Cardiovasc Toxicol; 2017 Jul; 17(3):307-318. PubMed ID: 27783203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protective effects of NAMPT or MAPK inhibitors and NaR on Wallerian degeneration of mammalian axons.
    Alexandris AS; Ryu J; Rajbhandari L; Harlan R; McKenney J; Wang Y; Aja S; Graham D; Venkatesan A; Koliatsos VE
    Neurobiol Dis; 2022 Sep; 171():105808. PubMed ID: 35779777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The small molecule GMX1778 is a potent inhibitor of NAD+ biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-deficient tumors.
    Watson M; Roulston A; Bélec L; Billot X; Marcellus R; Bédard D; Bernier C; Branchaud S; Chan H; Dairi K; Gilbert K; Goulet D; Gratton MO; Isakau H; Jang A; Khadir A; Koch E; Lavoie M; Lawless M; Nguyen M; Paquette D; Turcotte E; Berger A; Mitchell M; Shore GC; Beauparlant P
    Mol Cell Biol; 2009 Nov; 29(21):5872-88. PubMed ID: 19703994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nicotinic Acid Phosphoribosyltransferase Regulates Cancer Cell Metabolism, Susceptibility to NAMPT Inhibitors, and DNA Repair.
    Piacente F; Caffa I; Ravera S; Sociali G; Passalacqua M; Vellone VG; Becherini P; Reverberi D; Monacelli F; Ballestrero A; Odetti P; Cagnetta A; Cea M; Nahimana A; Duchosal M; Bruzzone S; Nencioni A
    Cancer Res; 2017 Jul; 77(14):3857-3869. PubMed ID: 28507103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitors of NAD
    Ghanem MS; Caffa I; Monacelli F; Nencioni A
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of Nicotinamide Phosphoribosyltransferase (NAMPT), an Enzyme Essential for NAD+ Biosynthesis, Leads to Altered Carbohydrate Metabolism in Cancer Cells.
    Tan B; Dong S; Shepard RL; Kays L; Roth KD; Geeganage S; Kuo MS; Zhao G
    J Biol Chem; 2015 Jun; 290(25):15812-15824. PubMed ID: 25944913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nicotinamide phosphoribosyltransferase promotes epithelial-to-mesenchymal transition as a soluble factor independent of its enzymatic activity.
    Soncini D; Caffa I; Zoppoli G; Cea M; Cagnetta A; Passalacqua M; Mastracci L; Boero S; Montecucco F; Sociali G; Lasigliè D; Damonte P; Grozio A; Mannino E; Poggi A; D'Agostino VG; Monacelli F; Provenzani A; Odetti P; Ballestrero A; Bruzzone S; Nencioni A
    J Biol Chem; 2014 Dec; 289(49):34189-204. PubMed ID: 25331943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.